Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

BACKGROUND: ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. The first-in-human trial of ONC201 previously established a recommended phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Mark N., Malhotra, Jyoti, Tarapore, Rohinton S., Malhotra, Usha, Silk, Ann W., Chan, Nancy, Rodriguez, Lorna, Aisner, Joseph, Aiken, Robert D., Mayer, Tina, Haffty, Bruce G., Newman, Jenna H., Aspromonte, Salvatore M., Bommareddy, Praveen K., Estupinian, Ricardo, Chesson, Charles B., Sadimin, Evita T., Li, Shengguo, Medina, Daniel J., Saunders, Tracie, Frankel, Melissa, Kareddula, Aparna, Damare, Sherrie, Wesolowsky, Elayne, Gabel, Christian, El-Deiry, Wafik S., Prabhu, Varun V., Allen, Joshua E., Stogniew, Martin, Oster, Wolfgang, Bertino, Joseph R., Libutti, Steven K., Mehnert, Janice M., Zloza, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532211/
https://www.ncbi.nlm.nih.gov/pubmed/31118108
http://dx.doi.org/10.1186/s40425-019-0599-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532211/
https://www.ncbi.nlm.nih.gov/pubmed/31118108
http://dx.doi.org/10.1186/s40425-019-0599-8

Ejemplares similares